Willow Prescription Process: How the GLP-1 Telehealth Platform Works for Women

What Willow Actually Is

Willow operates as a direct-to-consumer telehealth company that connects women with licensed prescribers for GLP-1 receptor agonist therapy. The platform does not manufacture medications or conduct its own clinical trials. It functions as an intermediary between patients and prescribers, with fulfillment handled through partner compounding pharmacies or retail pharmacy networks.

This distinction matters. The drugs Willow prescribes (semaglutide, tirzepatide) have well-established efficacy data from large randomized controlled trials. In STEP 1 (N=1,961), semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo [1]. The SURMOUNT-1 trial (N=2,539) showed tirzepatide at the highest dose (15 mg) achieved 22.5% mean weight reduction at 72 weeks [2]. These results belong to the molecules, not to any particular telehealth brand.

What varies between platforms is how well they screen patients, how qualified their prescribers are, how they handle dose titration, and whether they maintain adequate follow-up. That is where Willow should be evaluated.

The Intake Process Step by Step

Willow's onboarding follows a pattern common across GLP-1 telehealth platforms, with some women's-health-specific additions. The process begins with an online questionnaire that collects medical history, current medications, reproductive status, and weight management goals.

The questionnaire asks about BMI (the platform uses the same FDA-aligned eligibility thresholds as brand-name drug labels: BMI of 30 or higher, or 27 or higher with a comorbidity such as hypertension, type 2 diabetes, or dyslipidemia) [3]. It also screens for contraindications including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy or active breastfeeding.

After questionnaire submission, a licensed prescriber reviews the case. Depending on state telemedicine regulations, the consultation may be asynchronous (message-based review with follow-up questions) or synchronous (live video visit). States like those governed by the Ryan Haight Act have specific requirements for prescribing certain medications via telehealth, though GLP-1 agonists are not controlled substances and face fewer restrictions [4].

Most patients report receiving a prescribing decision within 24 to 48 hours. If approved, medication ships directly. The initial dose follows standard titration protocols: semaglutide typically starts at 0.25 mg weekly for four weeks before escalating, consistent with the prescribing information for Wegovy [5].

Compounded vs. Brand-Name GLP-1s Through Willow

One of the most consequential decisions in the Willow intake process is whether a patient receives a compounded or brand-name formulation. This is not a minor distinction.

Brand-name semaglutide (Wegovy) and tirzepatide (Zepbound) have undergone Phase III clinical trials with thousands of participants and carry FDA approval. Compounded semaglutide, by contrast, is prepared by 503A or 503B compounding pharmacies under the FDA's compounding framework and has not been independently evaluated in large trials for safety or efficacy [6]. The FDA issued a safety alert in 2023 warning that some compounded semaglutide products used salt forms (such as semaglutide sodium) that are not the same as the FDA-approved formulation [3].

Dr. Caroline Apovian, a co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, stated in a 2024 interview: "Patients need to understand that a compounded peptide is not a generic. It has not been tested in the same rigorous manner as the branded product, and dosing equivalence is not guaranteed."

Willow, like many telehealth platforms, has offered compounded semaglutide at lower price points than brand-name options. Patients should ask three questions before accepting a compounded prescription: Which pharmacy compounds it? Is it a 503B outsourcing facility (subject to FDA oversight) or a 503A pharmacy (less regulated)? And what salt form of semaglutide is being used?

Clinical Screening and Safety Protocols

A legitimate GLP-1 prescribing process requires more than a BMI check. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends that prescribers assess cardiovascular risk factors, screen for eating disorders, evaluate thyroid function, and review concomitant medications before initiating therapy [7].

Willow's intake questionnaire addresses some of these domains. The platform screens for thyroid cancer history, pregnancy, and major medication interactions. Whether the depth of screening matches what a face-to-face obesity medicine specialist would perform is an open question, and one that applies to all asynchronous telehealth platforms, not just Willow.

Gastrointestinal side effects are the most common reason patients discontinue GLP-1 therapy. In STEP 1, 44.2% of semaglutide patients reported nausea (vs. 17.4% on placebo), and 24.1% reported diarrhea [1]. Proper dose titration reduces these effects significantly. A platform's titration protocol and provider responsiveness to side-effect complaints are direct indicators of clinical quality. Willow states it conducts monthly check-ins for dose adjustments. Patients should confirm this actually occurs and that a licensed provider (not just a customer support representative) handles the interaction.

The American Gastroenterological Association's 2024 guideline on anti-obesity pharmacotherapy further recommends that prescribers discuss the likelihood of weight regain after medication discontinuation, as STEP 1 extension data showed participants regained approximately two-thirds of lost weight within one year of stopping semaglutide [8]. Any responsible intake process should include this conversation.

How Willow Compares to Other GLP-1 Telehealth Platforms

The telehealth GLP-1 market has become crowded. Platforms like Ro, Hims/Hers, Calibrate, Found, and Henry Meds compete alongside Willow. Differentiators fall into a few categories: prescriber qualifications, medication sourcing, follow-up intensity, pricing, and clinical programming beyond the prescription.

Willow markets itself specifically toward women, incorporating reproductive health considerations into its intake process. This has clinical merit. Sex-based differences in GLP-1 response are real. A post-hoc analysis of the STEP trials found that women experienced slightly higher rates of gastrointestinal adverse events than men, and hormonal fluctuations across the menstrual cycle can influence appetite regulation and medication tolerability [9].

Some platforms (notably Calibrate) pair GLP-1 prescriptions with structured behavioral programming including dietary coaching, sleep optimization, and exercise guidance. The SELECT trial (N=17,604) demonstrated cardiovascular benefits of semaglutide 2.4 mg independent of weight loss, with a 20% reduction in major adverse cardiovascular events over a mean follow-up of 39.8 months [10]. This finding strengthened the case for GLP-1 therapy even in patients with modest weight loss, but lifestyle modification remains a cornerstone of obesity management guidelines from the Endocrine Society [7].

Willow's positioning as a women's-focused platform is a marketing distinction that could carry clinical weight if it translates into sex-specific dosing awareness, fertility counseling, and PCOS screening. Whether it does so consistently depends on the individual prescriber.

Pricing and the Cash-Pay Model

Willow operates on a subscription model without insurance billing. This is standard across most GLP-1 telehealth platforms. Monthly costs vary depending on whether the patient receives compounded or brand-name medication.

Brand-name Wegovy carries a list price of approximately $1,349 per month without insurance, according to Novo Nordisk's pricing page. Compounded semaglutide through telehealth platforms typically ranges from $199 to $499 per month, though pricing varies by dose and pharmacy. Willow's pricing falls within this range for compounded formulations.

Dr. Fatima Cody Stanford, an obesity medicine specialist at Massachusetts General Hospital and associate professor at Harvard Medical School, has noted: "Cost remains the single largest barrier to GLP-1 access. When patients choose compounded medications purely on price, they may be trading a known safety profile for an unknown one. That tradeoff deserves an explicit, informed conversation."

Patients considering Willow should also factor in the cost of recommended lab work (metabolic panels, HbA1c, lipid profiles), which the platform may or may not cover in its subscription fee. Out-of-pocket lab costs at commercial draw centers typically run $50 to $150 per panel.

Is Willow Legitimate?

This question appears frequently in search queries, and it deserves a direct answer. Willow is a legally operating telehealth platform that uses licensed prescribers. That baseline of legitimacy does not exempt it from scrutiny.

Red flags to watch for in any GLP-1 telehealth platform (Willow included) are: prescriptions issued without meaningful medical review, no contraindication screening for medullary thyroid carcinoma or MEN2, use of 503A compounding pharmacies without FDA oversight, no structured follow-up or dose titration plan, and no discussion of weight regain risk upon discontinuation [1].

Green flags include: synchronous video consultations (not just questionnaire-only prescribing), use of 503B outsourcing facilities or brand-name medications, documented titration schedules matching FDA-approved labeling, required lab work, and provider-led monthly check-ins with clinical documentation [5].

Patients should verify that the prescriber listed on their prescription holds an active medical license in their state. This can be checked through state medical board databases. The prescriber should be a physician (MD or DO), nurse practitioner, or physician assistant practicing within their scope.

Women's Health Considerations for GLP-1 Therapy

Willow's focus on women's health raises specific clinical questions that any patient considering the platform should understand.

GLP-1 receptor agonists are contraindicated in pregnancy based on animal reproductive toxicity data [3]. The FDA recommends discontinuing semaglutide at least two months before a planned pregnancy due to its long half-life of approximately seven days. Tirzepatide carries similar warnings. A responsible women's-focused platform must actively screen for pregnancy intent and provide clear washout guidance.

For women with polycystic ovary syndrome (PCOS), GLP-1 therapy shows particular promise. A 2024 systematic review published in The Lancet Diabetes & Endocrinology found that GLP-1 receptor agonists improved ovulation rates, reduced androgen levels, and decreased insulin resistance in women with PCOS, with effects that exceeded those of metformin alone [11]. If Willow's intake process identifies PCOS and adjusts clinical monitoring accordingly, that represents meaningful clinical differentiation.

Perimenopausal and postmenopausal women face distinct metabolic challenges. The decline in estradiol accelerates visceral fat accumulation and increases cardiovascular risk. The Endocrine Society recommends considering anti-obesity pharmacotherapy as an adjunct to lifestyle modification in postmenopausal women with a BMI of 30 or higher [7]. A platform that understands this hormonal context can provide more nuanced care than a gender-neutral one.

What Happens After the Prescription

The prescription is the beginning, not the end. Long-term outcomes with GLP-1 therapy depend on sustained use, appropriate titration, side-effect management, and integration with lifestyle changes.

Data from the STEP 4 trial showed that patients who continued semaglutide 2.4 mg for 68 weeks maintained a 17.4% weight loss, while those switched to placebo at week 20 regained weight and ended with only 5.0% loss from baseline [12]. This finding carries a clear clinical message: stopping the medication without a transition plan leads to regain.

Willow's monthly check-in model should, at minimum, cover: current weight and vital signs, gastrointestinal symptom assessment, dose titration decisions, medication supply and adherence, and long-term planning including when or whether to attempt discontinuation. Patients who find that follow-up visits consist of brief questionnaires with no provider interaction should consider whether the platform is meeting the standard of care.

The best outcome from any GLP-1 telehealth platform is a patient who understands their medication, receives appropriate monitoring, and has a prescriber who adjusts the treatment plan based on clinical response rather than a one-size-fits-all protocol. That standard applies to Willow and every competitor equally.

Semaglutide 2.4 mg requires a five-step titration over 16 weeks (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, then 2.4 mg) per Wegovy's FDA label, and skipping steps increases nausea risk substantially [5].